<DOC>
	<DOCNO>NCT02872649</DOCNO>
	<brief_summary>Patients severe heart failure support leave ventricular assist device ( LVAD ) require adequate long-term anticoagulant therapy . New oral anticoagulant direct thrombin inhibitor dabigatran may represent alternative Coumarin long-term anticoagulation . In pilot single-center study , thirty LVAD patient stable renal function schedule receive phenprocoumon dabigatran long-term anticoagulation implantation HeartWare HVAD system follow open-label balance parallel group design .</brief_summary>
	<brief_title>Dabigatran Alternative Anticoagulant Patients With Left Ventricular Assist Device ( LVAD )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Phenprocoumon</mesh_term>
	<criteria>LVAD ( HVAD , Heartware Inc. , Framingham , MA , USA ) implantation one month ago Stable renal function ( clinical judgement ) Age 18 year old Ability give inform consent Severe chronic renal impairment ( CL &lt; 30 ) History significant thromboembolic event Significant bleed disorder HIV Hepatitis C infection Heparin induce thrombocytopenia Known hypersensitivity Dabigatran Phenprocoumon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>